CDT Equity Inc. (CDT)
| Market Cap | 11.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -39.22M |
| Shares Out | 4.86M |
| EPS (ttm) | -1,177.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,898 |
| Open | 2.490 |
| Previous Close | 2.490 |
| Day's Range | 2.380 - 2.490 |
| 52-Week Range | 2.390 - 1,754.399 |
| Beta | 2.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 15, 2026 |
About CDT
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation developm... [Read more]
Financial Performance
Financial StatementsNews
CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a ...
What's Going On With CDT Equity Shares On Monday?
• CDT Equity stock is among today's top performers. What's behind CDT gains?
CDT Notes Sarborg Publication of PRISM Framework Expanding AI
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the p...
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that fu...
CDT Equity Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reve...
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that it has completed initial signature mapping o...
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meetin...
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the e...
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”)...
CDT Positions for Transformational Growth
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder valu...
CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarborg Limite...
CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has entered into a strategic transaction t...
CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 02, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has engaged NJS Foresight Bio-Advisory, LL...
CDT Equity Increases Bitcoin Holding
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the acquisition of 9.25648743 Bitcoin (“BTC”) for ...
CDT Executes Cryptocurrency Treasury Reserve Strategy
NAPLES, Fla. And CAMBRIDGE, United Kingdom, Sept.
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Aug. 26, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announces that it has successfully identified a new biologica...
Conduit to Change Name to CDT Equity Inc.
Name change to CDT Equity Inc. reflects evolution of strategy and focus on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation, strategic partnerships...
Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy
Independent advisor appointed to assess feasibility and strategic benefit of a partial cryptocurrency-based treasury reserve Initiative aims to diversify capital positioning while retaining focus on I...
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with...
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal...
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life scienc...
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE N...
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life scienc...
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company...
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit's pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formul...